InflaRx N.V. - IFRX STOCK NEWS

InflaRx N.V. (Nasdaq: IFRX) announced encouraging results from its Phase IIa study of vilobelimab in Pyoderma Gangraenosum (PG), with four out of ten evaluable patients showing a clinical response at day 99. Three patients achieved complete closure of their target lesions, with treatment being well tolerated and no significant adverse events during dose escalation. The study enrolled 19 patients, with doses of vilobelimab ranging from 800mg to 2400mg. The ongoing study aims to assess vilobelimab's efficacy and safety further, especially in the higher dose cohort.

InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company, will present at the BTIG Virtual Biotechnology Conference on August 10, 2021. The event will feature a fireside chat with CEO Prof. Niels C. Riedemann, discussing the company's pipeline and upcoming catalysts at 9:00 am EDT. InflaRx is focused on developing first-in-class inhibitors of C5a, a key inflammatory mediator involved in various autoimmune diseases. Founded in 2007, the company operates in Germany and the USA.

InflaRx announced significant progress in its clinical trials and a financial update for Q2 2021. The severe COVID-19 trial has enrolled 299 patients, with an independent data monitoring committee recommending continuation. A Type A meeting has been requested with the FDA regarding the Phase III study for Hidradenitis Suppurativa. The first patients have been dosed in a Phase II trial for Cutaneous Squamous Cell Carcinoma. As of June 30, 2021, financial assets total approximately €127.5 million, though the company reported a net loss of €20.9 million for the first half of 2021.

InflaRx N.V. (Nasdaq: IFRX) will virtually present at the Raymond James Human Health Innovation Conference from June 21-23, 2021. Prof. Niels C. Riedemann, CEO and Founder, will engage in a fireside chat on June 23 at 10:00 am EDT, discussing the company's pipeline and forthcoming catalysts. A live webcast will be available on InflaRx's website, with a replay accessible post-event. The company specializes in developing anti-inflammatory therapeutics targeting the complement system, specifically using its proprietary anti-C5a technology.

InflaRx N.V. (Nasdaq: IFRX) has initiated a Phase II clinical trial evaluating vilobelimab, both as a standalone treatment and in combination with pembrolizumab, for patients with PD-1 or PD-L1 inhibitor-resistant locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC). The trial aims to enroll around 70 patients and assess the safety and anti-tumor efficacy of vilobelimab. Given the poor prognosis of advanced cSCC, the development of vilobelimab, a monoclonal antibody targeting C5a, could provide vital treatment options for patients.

InflaRx N.V. (Nasdaq: IFRX) announced the appointment of Tony Gibney as a Non-Executive Director to its Board, approved by shareholders at the 2021 annual meeting. Gibney, a seasoned biotech executive and former investment banker, brings extensive experience in financing and M&A transactions. He aims to support InflaRx's strategy in complement C5a inhibition, a critical area for autoimmune diseases. Mark Kübler and Lina Ma were re-elected as board members, who have significantly contributed to the company since its IPO in 2017.

InflaRx reported progress in several clinical trials, including reaching 178 patients in its severe COVID-19 trial, with an interim analysis expected in Q3 2021. The company is preparing to discuss the primary endpoint for its Phase III trial of vilobelimab in Hidradenitis Suppurativa with the FDA. Financially, as of March 31, 2021, InflaRx held approximately €137.8 million in cash and equivalents. In Q1 2021, net loss decreased to €6.1 million from €8.2 million year-over-year. Overall, the company is focused on advancing its clinical programs and has observed a decline in R&D expenses.

InflaRx has announced positive topline results from its U.S. Phase II IXPLORE trial for vilobelimab, demonstrating safety and tolerability in patients with ANCA-associated vasculitis (AAV). The study, involving 19 patients, showed no safety concerns and highlighted favorable clinical responses. Vilobelimab was well received alongside standard care, with 85.7% of patients on 400 mg and 75% on 800 mg achieving remission by week 16. The ongoing EU IXCHANGE trial is fully enrolled, with results anticipated by the end of 2021, potentially paving the way for further development of vilobelimab in AAV.

InflaRx N.V. (Nasdaq: IFRX) announced that it has successfully enrolled 18 patients in its Phase IIa study of vilobelimab for treating Pyoderma Gangraenosum (PG). This open-label study is designed to evaluate the safety and efficacy of vilobelimab, with interim results expected by the end of 2021 and final results anticipated in 2022. Initial data from five patients showcased promising healing results. PG is a debilitating autoimmune disease with no FDA-approved treatments, highlighting the potential significance of vilobelimab in patient care.